Both preclinical and clinical studies examining MSLN expression in mesothelioma, pancreatic cancer, and lung adenocarcinoma show evidence that enhanced MSLN expression portends a reduction in survival in animals and humans [13, 14, 17, 18]. The gene discussed is MSLN; the disease is familial pancreatic carcinoma.